Rodríguez SO, Reyes AMC

Language: Spanish
References: 20
Page: 12-17
PDF size: 150.86 Kb.

ABSTRACT

To evaluate the efficacy and safety sublingual immunotherapy (SLIT), it revised the register of patients of Previsora, Camagüey. The sample, 62 infants of 6 to 24 months with rhinitis and/or asthma sensitized Dermatophagoides pteronyssinus, Dermatophagoides siboney and Blomia tropicalis mite. It received SLIT 34 young and 28 measures of environmental control. All received medicines to demanding. Applied some questions of the Rhinitis Quality of Life in Questionnaires (RQLQ) and asthma (AQLQ) of Juniper; consumption of medicines and frequency of crisis. It is made subjective valuation to familiar and medical of the state of health of the child before the trade lie and after the same thing. Evaluated react premises and systemic to the proof and to SLIT. It had increment of the punctuation of the questionnaires of quality of life (p = 0.033). The consumption of medicines it went down more in the controls (p = 0.003). The frequency of respiratory symptomatology decreased (p = 0.029). For the sample before, of the treatment, the punctuation of the subjective valuation was negative. After the treatment, 85% of the obtaining cases 5 points, 15% between 3 and 4 points. In the controls 55% to obtaining 5 points, 10% between 3 and 4 points and 5% being 0 and 2 points (p = 0.011). It had not adverse reaction to the skin test; reported two react light premises SLIT. The results reveal that the sublingual immunotherapy with mites for below two years children’s is suffer rhinitis and asthma is effective and sure.

REFERENCES

1. Declaración de Helsinki de la Asociación Médica Mundial. ARBOR Ciencia, Pensamiento y Cultura CLXXXIV 730. 2008; 349-352.

2. Pautas éticas internacionales para la investigación biomédica en seres humanos. Programa Regional de Bioética OPS/OMS. Disponible en: http://www.bioetica.ops-oms.org/

3. Buenas prácticas clínicas: documento de las Américas. IV Conferencia Panamericana para la armonización de la reglamentación farmacéutica. República Dominicana. OPS, OMS. 2-4 Marzo 2005.

4. Wen CJ, Zhu MF, Ren WM, Liu XY, Qian H. Clinical efficacy and safety of sublingual immunotherapy using standardized Dermatophagoides farinae extract for children with combined allergic rhinitis and asthma syndrome. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011; 46 (5): 393-396.

5. Li TY, Chen DH, Lin ZB, Xu R. Efficacy of sublingual immunotherapy with Dermatophagoides farinae drops in patients with allergic rhinitis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011; 46 (10): 859-862.

6. Li P, Li Q, Huang Z, Chen W, Lu Y, Tian M. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases. Int Forum Allergy Rhinol. 2014; 4 (10): 796-801.

7. Trebuchon F, Lhéritier-Barrand M, David M, Demoly P. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. Clin Transl Allergy. 2014; 4: 15.

8. de Bot CM, Moed H, Berger MY, Röder E, Hop WC, de Groot H et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr Allergy Immunol. 2012; 23 (2): 150-158.

9. Han DH, Choi YS, Lee JE, Kim DY, Kim JW, Lee CH et al. Clinical efficacy of sublingual immunotherapy in pediatric patients with allergic rhinitis sensitized to house dust mites: comparison to adult patients. Acta Otolaryngol. 2012; 132 (Suppl. 1): S88-93.

10. Corzo JL, Carrillo T, Pedemonte C, Plaza-Martin AM, Martín-Hurtado S, Dige E et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. J Investig Allergol Clin Immunol. 2014; 24 (3): 154-161.

11. Luo R, Liu W, Wang J, Chen Y, Sun C, Zhou L et al. Role of BAFF in pediatric patients with allergic rhinitis during sublingual immunotherapy. Eur J Pediatr. 2014; 173 (8): 1033-1040.

12. Aydogan M, Eifan AO, Keles S, Akkoc T, Nursoy MA, Bahceciler NN et al. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Respir Med. 2013; 107 (9): 1322-1329.

13. Dalkan C, Galip N, Tekguc H, Cobanoglu N, Bahceciler N. High prevalence of allergy in North Cypriot children. Paediatr Int Child Health. 2014; 34 (1): 37-42.

14. Frati F, Cecchi L, Scala E, Ridolo E, Dell’Albani I, Makrì E et al. New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis. Biologics. 2014; 8: 221-226.

15. Rodríguez SO, Labrada A, Célio R, Aboukhair F, Meli VR, Barata HJ et al. Comparación de la potencia de extractos alergénicos de ácaros en pacientes con asma y rinitis alérgica. Vaccimonitor. 2012; 21 (1): 25-29.

16. Rodríguez SO. Inmunoterapia sublingual en rinitis alérgica y asma en niños de dos a cinco años sensibilizados con ácaros. Rev Alerg Mex. 2008; 55 (2): 71-75.

17. Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013; 13 (11): 1543-1556.

18. Tao L, Shi B, Shi G, Wan H. Efficacy of sublingual immunotherapy for allergic asthma: retrospective meta-analysis of randomized, double-blind and placebo-controlled trials. Clin Respir J. 2014; 8 (2): 192-205.

19. Lin Z, Zhou L, Luo X, Xia W, Chen D, Xu R et al. Suppression of TIM-1 predicates clinical efficacy of sublingual immunotherapy for allergic rhinitis in children. Int J Pediatr Otorhinolaryngol. 2013; 77 (8): 1345-1349.

20. Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol. 2013; 132 (6): 1322-1336.